<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF9AA84F-ED5C-41C7-AE08-655128299AD1"><gtr:id>CF9AA84F-ED5C-41C7-AE08-655128299AD1</gtr:id><gtr:name>Nanoco</gtr:name><gtr:address><gtr:line1>48 Grafton Street</gtr:line1><gtr:line4>Manchester</gtr:line4><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C41B3726-9589-48C4-A323-7A6B005207BA"><gtr:id>C41B3726-9589-48C4-A323-7A6B005207BA</gtr:id><gtr:name>Cyprotex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1988ADD6-0109-436C-A228-7AA7CC68C046"><gtr:id>1988ADD6-0109-436C-A228-7AA7CC68C046</gtr:id><gtr:name>AB SCIEX</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/227C3B24-E8A5-4F31-B62A-F3B73D5C74D8"><gtr:id>227C3B24-E8A5-4F31-B62A-F3B73D5C74D8</gtr:id><gtr:name>LEO Pharma (including subsidiary Peplin Ltd)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B30553BA-EA24-4867-8BB9-C85ABE020F22"><gtr:id>B30553BA-EA24-4867-8BB9-C85ABE020F22</gtr:id><gtr:name>Galen Research Ltd</gtr:name><gtr:address><gtr:line1>Enterprise House</gtr:line1><gtr:line2>Manchester Science Park</gtr:line2><gtr:line3>Lloyd Street North</gtr:line3><gtr:postCode>M15 6SE</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A4E9AD53-63D6-4F7C-AD47-2214D4258F75"><gtr:id>A4E9AD53-63D6-4F7C-AD47-2214D4258F75</gtr:id><gtr:name>SynAging SAS</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C"><gtr:id>BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C</gtr:id><gtr:name>Waters Corporation / Micromass U K Ltd</gtr:name><gtr:address><gtr:line1>Floats Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M23 9LZ</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF9AA84F-ED5C-41C7-AE08-655128299AD1"><gtr:id>CF9AA84F-ED5C-41C7-AE08-655128299AD1</gtr:id><gtr:name>Nanoco</gtr:name><gtr:address><gtr:line1>48 Grafton Street</gtr:line1><gtr:line4>Manchester</gtr:line4><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C41B3726-9589-48C4-A323-7A6B005207BA"><gtr:id>C41B3726-9589-48C4-A323-7A6B005207BA</gtr:id><gtr:name>Cyprotex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1988ADD6-0109-436C-A228-7AA7CC68C046"><gtr:id>1988ADD6-0109-436C-A228-7AA7CC68C046</gtr:id><gtr:name>AB SCIEX</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/227C3B24-E8A5-4F31-B62A-F3B73D5C74D8"><gtr:id>227C3B24-E8A5-4F31-B62A-F3B73D5C74D8</gtr:id><gtr:name>LEO Pharma (including subsidiary Peplin Ltd)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B30553BA-EA24-4867-8BB9-C85ABE020F22"><gtr:id>B30553BA-EA24-4867-8BB9-C85ABE020F22</gtr:id><gtr:name>Galen Research Ltd</gtr:name><gtr:address><gtr:line1>Enterprise House</gtr:line1><gtr:line2>Manchester Science Park</gtr:line2><gtr:line3>Lloyd Street North</gtr:line3><gtr:postCode>M15 6SE</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A4E9AD53-63D6-4F7C-AD47-2214D4258F75"><gtr:id>A4E9AD53-63D6-4F7C-AD47-2214D4258F75</gtr:id><gtr:name>SynAging SAS</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C"><gtr:id>BF6E9D7C-AF75-47D4-8EE8-CACFD251EB6C</gtr:id><gtr:name>Waters Corporation / Micromass U K Ltd</gtr:name><gtr:address><gtr:line1>Floats Road</gtr:line1><gtr:line2>Wythenshawe</gtr:line2><gtr:line4>Manchester</gtr:line4><gtr:postCode>M23 9LZ</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/320A9E84-D5A3-4BDD-9BAB-9BEC4AAB40E4"><gtr:id>320A9E84-D5A3-4BDD-9BAB-9BEC4AAB40E4</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Schroder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/70B8FE42-6AEE-4487-A0AE-EE27211F6CBC"><gtr:id>70B8FE42-6AEE-4487-A0AE-EE27211F6CBC</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Humphries</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/485F21B4-25E2-42BA-B379-E9907F855BF7"><gtr:id>485F21B4-25E2-42BA-B379-E9907F855BF7</gtr:id><gtr:firstName>Luke</gtr:firstName><gtr:surname>Georghiou</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/92856E07-3ABB-4DBF-8B61-5882206D3667"><gtr:id>92856E07-3ABB-4DBF-8B61-5882206D3667</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Andrew</gtr:otherNames><gtr:surname>Greer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_15058"><gtr:id>A2650B3F-AF52-4215-8034-DC6178B379AB</gtr:id><gtr:title>The University of Manchester - Proximity to Discovery: Industry Engagement Fund - Phase 2</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_15058</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.&amp;nbsp; The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers? understanding of each other?s needs and capabilities.&amp;nbsp; This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ?entrepreneurs in residence? schemes.&amp;nbsp; Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.</gtr:technicalSummary><gtr:fund><gtr:end>2018-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Galen Research Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration between Pete Bower and Galen Research Ltd</gtr:description><gtr:id>99C8CBA3-036A-4B1E-B03E-4B5942BB2190</gtr:id><gtr:impact>Still in progress.</gtr:impact><gtr:outcomeId>58c8392f5b06c8.65808794-1</gtr:outcomeId><gtr:partnerContribution>Training in psychometrics and measurement science to analyse and compare complex interventions.</gtr:partnerContribution><gtr:piContribution>Access to COPD patient cohort, and linked data with council (social) services, providing feasibility data concerning methods to assess integrated services.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cyprotex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration between Richard Bryce and Cyprotex</gtr:description><gtr:id>5AF43BAD-D34A-4C33-9915-95FFF9E7C521</gtr:id><gtr:impact>Still in progress.</gtr:impact><gtr:outcomeId>58c7d086480261.89489110-1</gtr:outcomeId><gtr:partnerContribution>In vivo PK datasets to improve lab's in silico models. 
Acces to existing proprietary PBPK software. 
Market specific knowledge to develop a business case for software development (e.g. informing whether open access framework needed and potential licencing arrangements).</gtr:partnerContribution><gtr:piContribution>Expertise in advanced molecular modelling techniques to replace simple 2D models currently used by company. 
Improving models based on in vivo PK datasets.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AB SCIEX</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration between Paul Townsend and SCIEX</gtr:description><gtr:id>C0438A41-9B50-4DA4-8035-22B72C683977</gtr:id><gtr:impact>Still in progress.</gtr:impact><gtr:outcomeId>58c9004305cc38.03833589-1</gtr:outcomeId><gtr:partnerContribution>Training and access to proprietary SWATH-MS systems.</gtr:partnerContribution><gtr:piContribution>Access to 200 serum samples from prostate cancer patients and healthy control groups.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Waters Corporation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Micromass UK Ltd</gtr:department><gtr:description>Collaboration between Anna Nicolaou and Waters</gtr:description><gtr:id>E3B04A57-FB9E-489F-A196-5777FD7EEB9D</gtr:id><gtr:impact>Project still in progress.</gtr:impact><gtr:outcomeId>58be9b38efc8e6.66620949-1</gtr:outcomeId><gtr:partnerContribution>Access to state of the art technology, and licences to associated software. 
Training of academic staff.</gtr:partnerContribution><gtr:piContribution>Application of novel company technologies to clinical samples, and data analysis to form an academic publication and subsequent grant proposals. 
Training of company staff in scientific techniques.
Project supervision.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Collaboration between Jo Neill and Roche</gtr:description><gtr:id>7FEDE9C2-297A-4C73-846A-C808FAC88C01</gtr:id><gtr:impact>Project in progress.</gtr:impact><gtr:outcomeId>58bec516c78046.97110604-1</gtr:outcomeId><gtr:partnerContribution>State of the art facilities and know how to culture brain cells. 
Training on co-culture of complex cell types.</gtr:partnerContribution><gtr:piContribution>Novel in vivo models for neurodevelopmental abnormalities, and related cell culture models to identify new biomarkers. Once validated, these biomarkers may be useful to monitor clinical trials, and the models used in drug discovery.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nanoco</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration between Catharine West and Nanoco Technologies Ltd</gtr:description><gtr:id>EF8DB06C-1F47-4DEB-917F-EFC65B2F6F15</gtr:id><gtr:impact>Still in progress.</gtr:impact><gtr:outcomeId>58c90246b16888.88911842-1</gtr:outcomeId><gtr:partnerContribution>Access to novel reagents to improve assay times and sensitivity.</gtr:partnerContribution><gtr:piContribution>An assay for a novel cancer biomarker to determine suitability for immunotherapy.
Access to patient samples for assay validation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>LEO Pharma (including subsidiary Peplin Ltd)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Collaboration between Helen Young and Leo Pharma</gtr:description><gtr:id>47707571-94C4-489A-B017-BC090D6B5808</gtr:id><gtr:impact>Still in progress.</gtr:impact><gtr:outcomeId>58c7d29c40f0e7.68991007-1</gtr:outcomeId><gtr:partnerContribution>Previous insight from studies into wearables and exercise programmes. 
A funded anthropologist to conduct interviews and workshops. 
Commercial experience in launching products and services for psoriasis patients.</gtr:partnerContribution><gtr:piContribution>A clinical tool to quantify amount of physical activity/adherence to exercise programmes for psoriasis patients, who typically do not exercise to recommended levels and increase their already elevated risk of cardiovascular disease.
Access to focus groups of psoriatic patients to inform programme design, trial the product, and give feedback.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SynAging SAS</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Collaboration between Michael Harte and Synaging</gtr:description><gtr:id>6B9C0592-480A-4BBB-A4AE-B6C35FE01B30</gtr:id><gtr:impact>Still in progress.</gtr:impact><gtr:outcomeId>58c7deb31c5b07.85195589-1</gtr:outcomeId><gtr:partnerContribution>Provision of transgenic cell lines.
Avenue to commercialise models generated.</gtr:partnerContribution><gtr:piContribution>Expertise in encapsulation technologies and surgical procedures to generate novel in vivo models. 
Analysis of models and investigation of disease biomarkers.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_15058</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>